Loading...

Scinai Immunotherapeutics Ltd.

SCNI•NASDAQ
HealthcareBiotechnology
$2.54
$-0.71(-21.85%)

Scinai Immunotherapeutics Ltd. (SCNI) Stock Overview

Explore Scinai Immunotherapeutics Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for SCNIStats details for SCNI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for SCNIAnalyst Recommendations details for SCNI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

CEO

Mr. Amir Reichman M.B.A., M.Sc.

Employees

31

Headquarters

Jerusalem BioPark Building, Jerusalem

Founded

2015

Frequently Asked Questions